Close Menu

Biocartis

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

This story has been updated from a previous version to include information about Biocartis' newly branded MDx platform and AACR presentation.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biocartis today announced that it has licensed from Hospital del Mar in Spain the rights to an EGFR biomarker for colon cancer.

Biocartis said this week that Ulrik Cordes has joined the company as chief commercial officer.

Biocartis of Lausanne, Switzerland, has been awarded US Patent No. 8,441,629, "Optical detection system for monitoring rtPCR reaction."

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

Cepheid disclosed in a filing with the US Securities and Exchange Commission this week that it has terminated the employment of Nicolaas Arnold, its executive vice president of worldwide commercial operations.

Molecular diagnostics firm Biocartis has hired Inge Basteleurs as its general counsel.

NEW YORK (GenomeWeb News) – Five years after its founding, Swiss molecular diagnostics firm Biocartis has transitioned to full commercial mode with the launch of its DMAT platform last week and the completion announced today of its Series D financing round bringing in €34.5 million ($45.0 million

Precision Therapeutics Assesses Multi-Gene Predictors of Breast Cancer Chemo Response

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.